



Plasmodium vivax malaria: related factors to severity in the State of Maranhão, Brazil

Camila Cristina Bastos Silva Raposo^[1], João Barberino Santos^[2],
Gisele Maria Campelo dos Santos^[3], Eloísa da Graça do Rosário Gonçalves^{[1],[4]}
and Antonio Rafael da Silva^{[1], [4]}

[1]. Centro de Referência em Doenças Infecciosas e Parasitárias, Departamento de Patologia, Universidade Federal do Maranhão, São Luis, MA. [2]. Núcleo de Medicina Tropical, Universidade de Brasília, Brasília, DF. [3]. Curso de Graduação em Medicina, Universidade Federal do Maranhão, São Luis, MA. [4]. Programa de Pós-Graduação em Saúde e Ambiente, Universidade Federal do Maranhão, São Luis, MA.

ABSTRACT

Introduction: Malaria caused by *Plasmodium vivax* species has shown signs of severity, recorded with increasing frequency in the medical literature. This study aimed to characterize the signs of severe malaria by *Plasmodium vivax* in the State of Maranhão, Brazil. **Methods:** A descriptive cohort study of patients assisted in the field and a historical and concurrent study of a series of cases among hospitalized patients were undertaken to identify the clinical and laboratory signs of severity. **Results:** A total of 153 patients were included in the study, 13 of whom were hospitalized. Males made up the majority, numbering 103 (67.3%). The age of the patients ranged from 10 to 70 years, 92.2% were natives of the State of Maranhão, and 65% of the patients had had malaria before. The average time elapsed between symptom onset and diagnosis among outpatients was three days, while among hospitalized patients this average reached 15.5 days, a statistically significant difference ($p=0.001$). The parasitemia ranged from 500 to 10,000 parasites/ μ l in 92.8% of cases. The clinical and laboratory manifestations of severity were vomiting and diarrhea, jaundice, drowsiness, mental confusion, seizures, loss of consciousness, agitation, bleeding, pale skin, coughing and dyspnea, thrombocytopenia, anemia, elevation of nitrogenous compounds, and elevated transaminases and bilirubin. **Conclusions:** The monitoring of malaria patients with *Plasmodium vivax* showed the possibility of aggravation, the intensity of which varied in different circumstances, especially the interval time between falling ill and diagnostic confirmation.

Keywords: Malaria. Severity. *Plasmodium vivax*. State of Maranhão.

INTRODUCTION

Malaria is one of the most important diseases that affect humans, occurring in all tropical regions of the planet and in more than 109 countries. It is one of the major causes of death from infectious diseases, resulting in more than 300 million clinical cases and approximately one million deaths per year¹. In Brazil, the incidence of malaria is concentrated in nine States of the Legal Amazon (Acre, Amazonas, Amapá, Rondônia, Roraima, Pará, Tocantins, Maranhão and Mato Grosso) and represents the main endemic disease in the State of Maranhão².

A systematic reduction in the number of malaria cases has been observed in the State of Maranhão since 2000, when an intensified program to control malaria in the Amazon Region was implemented. In 2005 a total of 9,110 cases were diagnosed, of which 7,352 (80.7%) were by *Plasmodium vivax*³. In the following years this tendency continued, reaching a total of 3,904 cases in 2010, with 3,000 (76.8%) by *Plasmodium vivax*⁴.

There is little information about the severity and possible related deaths from malaria by *Plasmodium vivax*, which

usually manifests as a benign disease. Atypical manifestations and severe forms, however, have been registered and are characterized in particular by thrombocytopenia, jaundice, changes in level of consciousness, and severe anemia⁵⁻¹⁰. These events warn that more accurate observations of the disease should be made, especially in geographical areas where the species is predominant.

METHODS

Descriptive study of malaria cases with manifestations of severity assisted at ambulatory, from January to October 2005, in Buriticupu, State of Maranhão, Brazil

Located in the western region of the state, the municipality of Buriticupu integrates the administrative region of Açailândia. As an old area of agricultural settling, it occupies an area of 2,719km² consisting of equatorial forest, in transition with other ecosystems. The population is composed of 65,237 inhabitants¹¹, and agriculture and wood extraction are the main economic activities. The municipality counts on the health service of the *Universidade Federal do Maranhão*, which also attends to patients from other municipalities.

In 2005 a total of 1,574 examinations were performed for malaria diagnosis. This resulted in 332 positive cases, of which 292 were for *Plasmodium vivax*. Of this total, only 33 were autochthonous from the municipality. The others originated from other cities, states, and countries.

Historical and concurrent study from a series of cases with clinical and laboratorial manifestations of severity in patients hospitalized

Address to: Dr. Antonio Rafael da Silva, Centro de Referência em Doenças Infecciosas e Parasitárias/Depto. de Patologia/UFMA. Praça Madre Deus 02, Térreo, Bairro Madre Deus, 65025-560 São Luis, MA, Brasil.

Phone: 55 98 3221-0270

e-mail: credip@ufma.br

Received in 09/07/2011

Accepted in 30/09/2011

in public and private general hospitals in São Luis, capital of State of Maranhão, Brazil, from January 1999 to December 2008.

Located in the western part of the Island of São Luis, the municipality of São Luis occupies an area of 831,700km² and has a population of 966,989 inhabitants¹¹. Patients with malaria were attended to by members of our team who routinely answer the calls from those care centers. Their clinical and laboratorial data were registered in specific form.

Inclusion criteria to the two phases of study were patients older than two years old and with a definite diagnosis of mono-infection by *Plasmodium vivax* malaria. Those with mixed infection, pregnant women, and patients with recognized chronic degenerative diseases and with clinical and/or laboratorial evidence of co-morbidities were excluded.

To investigate possible co-morbidities a detailed review of the medical records of all patients that had been attended to in Buriticupu was performed. Moreover, for inpatients, hepatitis serology was applied to those presenting jaundice. Other specific exams (dengue, kala-azar, enteric (typhoid) fever, and cytomegalovirus serology and blood culture) were performed according to the particular situation.

Parasitological diagnosis was done by the technique of thick blood film, stained using Giemsa and examined under a light microscope with immersion objective increases from 750 to 1,000 times. To quantify the parasitemia a semi-quantitative classification of parasitemia was used, as proposed by Walker¹².

Since there are no official criteria of severe malaria by *Plasmodium vivax*, the severity of the clinical presentation in this study was established from the classification of Alecrim⁶, as modified: I) *Classical malaria*: classic signs and symptoms of malaria such as fever (axillary temperature >37.5°C), chills, sweating, headache, vomiting, hepatomegaly and/or splenomegaly; II) *Severe malaria*: signs and symptoms of malaria, associated with one or more of the following laboratory and clinical complications: jaundice (total bilirubin >2mg/dL), anemia (hematocrit <30%), seizures, hypoglycemia (blood glucose <60mg/dL), thrombocytopenia (platelets <100,000/mm³), bleeding, coma, shock, hemoglobinuric fever, renal failure, splenic rupture, pulmonary disorders.

Statistical analysis

For the statistical analysis, the chi-square test was used or categorical variables and Fisher's exact test was used when the frequency was less than five elements. To compare the parasitemia level and severity manifestations the parasitemia classification proposed by Alecrim⁶, as modified, was considered. Test of hypothesis to evaluate equality of means of days between falling ill and diagnostic confirmation of patients in ambulatory care and those who were hospitalized was employed, using distribution *t* of Student. For evaluating statistical significance a *p* value < 0.05 was considered.

Ethical considerations

The research protocol, under registration 021/2005, was approved by the Ethics Committee in Human Research, Faculty of Medicine, University of Brasília. The protocol meets the requirements of the National Council Health.

RESULTS

Study of patients assisted in ambulatory care

We included 140 patients in the field study according to inclusion criteria, i.e. with manifestation of severity. This

represented 1.9% of the total number of *Plasmodium vivax* malaria in the State of Maranhão in 2005³.

The majority of them were male, numbering 94 (67%). The patients' ages ranged from 10 to 70 years, with 102 (73.2%) over 15 years. In the period of the study there was no register of patients less than 10 years old presenting criteria for severe malaria.

Autochthonous cases of Maranhão totaled 122 (87.1%), coming from the municipalities of Buriticupu, Bom Jardim, Bom Jesus das Selvas, Alto Alegre do Pindaré, and Santa Luzia. Imported cases from other states or countries accounted for 11 (7.8%), coming from French Guyana, Suriname, and the State of Pará. The place of transmission could not be identified in 7 (5%) patients. Forty-three (30.7%) patients had malaria for the first time, seventy-one (50.7%) for the second time, 20 (14.2%) for the third time, and six (4.3%) for more than the third time. The parasitemia of 130 (92.8%) patients did not exceed 10,000 parasites/μl at the time of their diagnostic confirmation. Among the other 10 patients, only one had over 100,000 parasites/μl of blood. Considering the patients with primary infection, 38 (88.3%) had less than 10,000 parasites/μl. Only 5 (11.6%) in this group of patients presented parasitemia higher than 10,000 parasites/μl. Among those who had the disease for more than once, 91 (93.8%) had parasitemia less than 10,000/μl, while in five (5.1%) the parasitemia was higher than 10,000/μl. The statistical analysis showed no statistically significant difference between the variables of primary infection and parasitemia (*p*=0.176).

The maximum time elapsed between the onset of symptoms and the parasitological confirmation of diagnosis was 10 days, with an average of three days. For 60 (42.8%) patients, the elapsed time was 48 hours, and on this occasion 51 (36.4%) patients already had parasitemia between 500 and 10,000 parasites/μl. A comparison between the time shorter or longer than 48 hours and the levels of parasitemia presented by the patients (<10,000 and ≥10,000 parasites/mm³) showed no statistically significant association between these variables (*p*=0.636). The most frequent symptoms presented by patients were fever (100%), chills (99.3%), headache (99.3%), and sweating (86.4%). Among the manifestations of severity in this group of patients were gastrointestinal disorders, such as vomiting or diarrhea in 26 (18.5%), and jaundice in 3 (2.1%) patients. As for neurological disorders, the symptoms were agitation in 2 (1.4%), drowsiness in 2 (1.4%), mental confusion in 1 (0.7%), loss of consciousness in 2 (1.4%), and seizures in 2 (1.4%). Nine (6.4%) people had bleeding and 122 (87%) had cutaneous-mucosal pallor. With regard to respiratory disorders, 23 (16.4%) of the patients reported cough and 4 (2.9%) reported having had shortness of breath.

The association between the signs and symptoms of severity and the level of parasitemia was statistically significant in this sample, in the cases of mental confusion and agitation, while the variable bleeding showed a value of *p* very close to the considered significant value (Table 1).

Taking into account the average time elapsed from the onset of symptoms to the parasitological diagnosis (3 days), and

TABLE 1 - Association between the severity of signs and symptoms and parasitemia reported by patients with malaria by *Plasmodium vivax*, assisted in the ambulatory, State of Maranhão, Brazil, 2005-2008.

Signs and symptoms	Parasitemia				Total	
	≤10,000 (n=130)		>10,000 (n=10)		n	P
	n	%	n	%		
Vomiting/diarrhea	26	20.0	0	0.0	26	0.117
Jaundice	3	2.3	0	0.0	3	0.627
Drowsiness	2	1.5	0	0.0	2	0.693
Mental confusion	0	0.0	1	10.0	1	<0.001
Convulsion	2	1.5	0	0.0	2	0.693
Loss of consciousness	2	1.5	0	0.0	2	0.693
Agitation	1	0.8	1	10.0	2	0.018
Bleeding	7	5.4	2	20.0	9	0.069
Pallor	114	87.7	8	80.0	122	0.484
Dyspnea	4	3.1	0	0.0	4	0.574
Cough	22	16.9	1	10.0	23	0.569

TABLE 2 - Association between the signs and symptoms of severity and the time elapsed between the onset of symptoms and diagnosis of patients with malaria by *Plasmodium vivax*, assisted in the field, State of Maranhão, Brazil, 2005-2008.

Signs and symptoms	Time until the diagnosis				Total	
	≤ 3 days (n=99)		> 3 days (n=41)		n	P
	n	%	n	%		
Vomiting/diarrhea	22	22.2	4	9.8	26	0.840
Jaundice	3	3.0	0	0.0	3	0.260
Drowsiness	2	2.0	0	0.0	2	0.359
Mental confusion	1	1.0	0	0.0	1	0.518
Convulsion	2	2.0	0	0.0	2	0.359
Loss of consciousness	1	1.0	1	2.4	2	0.517
Agitation	2	2.0	0	0.0	2	0.359
Bleeding	6	6.7	3	7.3	9	0.783
Pallor	89	89.8	33	80.4	122	0.130
Dyspnea	2	2.0	2	4.9	4	0.335
Cough	17	17.1	6	14.6	23	0.712

relating it to the signs and symptoms of severity presented by patients, it was not possible to establish a statistically significant association for any variable studied in this group of patients (Table 2).

Regarding the number of malarial affections with symptoms and signs of severity, it was observed that the symptoms that may denote complication were not significantly associated with the primary infection (Table 3). The variable of diarrhea showed a *p* value to closer to the considered statistically significant value.

Study of hospitalized patients

We studied 13 patients admitted to hospitals in São Luis from 1999 to 2008. Twelve patients came from the following municipalities of Maranhão: São Luis, São José de Ribamar, Itapecuru, Grajaú, São Bento, and Icatú. One patient got the

infection in Pindaí, State of Amapá. Tables 4 and 5 present their clinical and laboratory data. The hepatitis serology performed on patients with jaundice was negative. Others exams, such as dengue, kala-azar, enteric (typhoid) fever, and cytomegalovirus serology and blood culture, were performed according to particular clinical conditions and were negative as well.

The age of these patients ranged from 10 to 58 years. All of them had primary infection and had time intervals between the disease and diagnostic confirmation from 6 to 41 days (mean 15.5 days). When the hypothesis of equality of this average was tested against the average time between the diagnosis and confirmation of the disease seen in ambulatory patients (3 days), the difference was found to be significant ($p=0.001$). The parasite count showed that only one patient had parasitemia higher than 10,000/ μ l.

TABLE 3 - Association between the signs and symptoms of severity and the number of malaria infections in patients with *Plasmodium vivax* malaria, assisted in the field, State of Maranhão, Brazil, 2005-2008.

Signs and symptoms	Number of malaria infections				Total	p
	primary		multi-infection			
	infection (n=43)		(n=96)	%		
	n	%		%		
Vomiting/diarrhea	4	9.3	22	22.9	26	0.059
Jaundice	1	2.3	2	2.1	3	0.779
Drowsiness	1	2.3	1	1.0	2	0.557
Mental confusion	1	2.3	0	0.0	1	0.134
Convulsion	1	2.3	1	1.0	2	0.557
Loss of consciousness	1	2.3	1	1.0	2	0.557
Agitation	0	0.0	2	2.1	2	0.340
Bleeding	3	7.0	6	6.3	9	0.703
Pallor	38	88.3	84	87.5	122	0.885
Dyspnea	2	4.7	2	2.1	4	0.225
Cough	10	23.2	12	12.5	22	0.082

TABLE 4 - Severe malaria caused by *Plasmodium vivax* in hospitalized patients, São Luis, State of Maranhão, Brazil, from 1999 to 2008.

Case (n)	Old (years)	Gender	Origin	Time to diagnosis (days)	Parasitemia (parasites/ μ l)	Signs of severity
1	26	M	Autochthonous	10	501-10.00	Jaundice + thrombocytopenia + renal insufficiency
2	33	M	Autochthonous	22	501-10.00	Jaundice+ thrombocytopenia+ anemia+ pulmonary disease
3	20	F	Autochthonous	25	501-10.00	Jaundice + anemia + thrombocytopenia
4	38	M	Autochthonous	12	501-10.00	Jaundice + thrombocytopenia
5	38	M	Autochthonous	15	501-10.00	Jaundice + thrombocytopenia + pulmonary disease + neurological disease + conjunctival hemorrhage
6	31	M	Autochthonous	16	501-10.00	Jaundice + anemia
7	26	M	Autochthonous	15	501-10.00	Jaundice + thrombocytopenia + anemia + neurological disease
8	58	M	Imported	9	10.001 a 100.000	Thrombocytopenia + neurological disease
9	36	F	Autochthonous	16	501-10.00	Neurological disease
10	29	M	Autochthonous	7	501-10.00	Jaundice + thrombocytopenia + anemia + neurological disease
11	11	M	Autochthonous	6	501-10.00	Jaundice + anemia + pulmonary disease + neurological disease + hematuria + gastrointestinal bleeding
12	10	M	Autochthonous	7	501-10.00	Jaundice + thrombocytopenia + neurological disease
13	21	F	Autochthonous	41	501-10.00	Jaundice + thrombocytopenia

M: male; F: female.

Among the identified signs of severity, jaundice was the most common, with one patient having developed cholecystitis without lithiasis. The neurological changes identified were dizziness, drowsiness, mental confusion, and loss of consciousness; the respiratory symptoms were dyspnea and pulmonary infiltrates seen on chest radiography.

The most frequent laboratorial complication was thrombocytopenia, with three (23%) patients having less than 50,000 platelets/ μ l and two of these patients having conjunctival

hemorrhage, hematuria, and gastrointestinal bleeding. Other manifestations of severity were anemia with hemoglobin levels below 10g%, hiperbilirubinemia above 5mg/dL, elevated transaminases, and elevated nitrogenous compounds.

All patients in the study, with the exception of a hospitalized patient who received artemisinin because of a gastrointestinal bleeding, were treated with chloroquine associated with primaquine and presented a good clinical response and negative parasitemia in the second day of treatment. There were no deaths in the follow-up.

TABLE 5 - Laboratory tests results of patients hospitalized with severe malaria by *Plasmodium vivax*, São Luis, State of Maranhão, Brazil, from 1999 to 2008.

Case (n)	Hg	Ht	Platelets	AST	ALT	U	Cr	TB	DB	IB
1	11.8	35	45,000	64	74	150	6.3	26.5	13	13.5
2	9	26	49,800	41	38	20	0.4	10.6	5.3	5.3
3	9	26	72,000	58	18	19	1.2	2.9	1.7	1.2
4	10.6	30.8	18,000	84	67	64	1.15	19.23	11.28	7.95
5	14.4	42.5	71,000	59	64	-	-	9.46	5.82	3.64
6	10.4	29.6	136,000	47.05	33.16	27	1	5.23	2.21	3.02
7	6.8	19.2	59,000	125	190	-	1.2	15.2	11	4.2
8	12.4	37.3	72,000	83	58	84	1	2.88	2.05	0.83
9	12.4	38.9	128,000	-	-	-	-	-	-	-
10	10.1	31.7	78,000	113	66	25	0.7	2.9	0.8	1.6
11	4.1	10.7	153,000	630	320	112	2.3	51.0	36.0	15.0
12	8	25.9	90,000	26	15	23	0.5	6.89	0.86	5.9
13	5.5	16	54,000	-	-	-	-	-	-	-

Hg: hemoglobin; Ht: hematocrit; AST: aspartate aminotransferase; ALT: alanine aminotransferase; U: urea; Cr: creatinine; TB: total bilirubin; DB: direct bilirubin; IB: indirect bilirubin.

DISCUSSION

The study presents some limitations, because it was composed of a retrospective part developed from data of patients attended in the field. At the beginning, the authors had difficulty defining the criteria of severe malaria by *Plasmodium vivax*, since there are no official criteria defined to this species. Thus, although the criteria of severity from Alecrim⁶ have not been published, they were adopted in this study considering the author first described such severe manifestations in the Brazilian Amazon.

For the same reason it was not possible to apply polymerase chain reaction, which would allow the exclusion of possible mixed infection. However, the good clinical and parasitic response to treatment with chloroquine exhibited by patients reinforced the diagnoses of infection by *Plasmodium vivax*.

Plasmodium vivax malaria, predominant in the State of Maranhão, is commonly considered a benign condition^{13,14}. However, clear signs of severity have been observed, and in some cases hospitalization is required due to medical complications, such as those that occurred in the 13 cases in this study.

Almost all the patients initially showed the classic clinical presentation of malaria, following the trend observed in endemic regions. However, even if this statement is true for these regions, atypical manifestations denoting severity have been observed in an increasing way^{6,8,15}. Signs and symptoms, such as vomiting, diarrhea, jaundice, drowsiness, mental confusion, seizures, loss of consciousness, bleeding, and dyspnea, that registered in a significant percentage of patients confirm these findings.

Anemia, described as one of the major aggravations of malaria, is usually recorded as more severe in children and pregnant women with malaria by *Plasmodium falciparum*^{16,17}.

It was not possible to confirm this observation in this study, since there were no children less than 10 years old with severity manifestations while pregnant women were excluded.

However, as can be seen in the clinical and laboratory data of 13 hospitalized patients, anemia can become a serious condition in *Plasmodium vivax* malaria, resulting in the need for blood transfusion, which occurred with four of our patients. The low frequency of neurological disorders among patients seen in the ambulatory contrasts with the high (58%) proportion among those hospitalized. Similarly, the occurrence of alterations in the respiratory, liver, and kidney functions are consistent with data reported by other authors in relation to malaria by *Plasmodium vivax*^{8,18,19}. Noteworthy is the finding of jaundice in 2.1% of patients treated in ambulatory and in 58% of hospitalized patients, a sign that can lead to misdiagnosis, as observed in some patients who received an initial diagnosis of hepatitis. Serology and other laboratorial exams that proved negative excluded this diagnosis and other conditions. Moreover, with the specific treatment of malaria there was a normalization of serum bilirubin levels in the following days after the introduction of anti-malarial drugs.

Mild to moderate thrombocytopenia often occurs in malaria^{6,9}, although only rarely manifests itself by spontaneous hemorrhages. In the present study the laboratory abnormality was documented more frequently among hospitalized patients. It was probably present in some patients treated in ambulatory. As verified by other authors^{6,9}, the platelet count also normalized right after treatment. The lack of correct diagnosis and lack of understanding by health professionals that malaria by *Plasmodium vivax* can develop with such manifestations may lead to the performance of inappropriate exams and treatment.

Patients with primary infection, as expected, showed higher parasitemia, presumably with the absence of acquired immunity in previous contact with *Plasmodium* sp. It was observed, however,

that although these patients presented higher levels of parasitemia, this was not statistically significant and did not reflect the severity of the disease in these patients. Parasite density has been identified as a sign of bad prognosis⁸. In this study, there was no statistical relation between the level of parasitemia and the severity of clinical manifestations. In the analysis of the manifestations of severity, only mental confusion and agitation appear to be associated with parasitemia higher than 10,000 parasites/ μ l.

The delay in confirming the diagnosis was not reflected in high parasitemia. However, as can be seen in the study of hospitalized patients, the delay in establishing the diagnosis and beginning the treatment had negative repercussions and seems to have been decisive in the development and intensity of severe manifestations. A good clinical response, parasitologic clearance in the first two days of treatment, and no occurrence of deaths show that complications are reversible with proper treatment.

Data on parasitemia at day 28 after treatment were not available for all the patients and thus did not allow an evaluation of the possible development of *in vivo* chloroquine resistance, in line with other studies in the Brazilian Amazon²⁰. Prospective studies need to be developed in the area for a better understanding of the issue.

The severity of *Plasmodium vivax* malaria may be associated with the circulating variant of the species in certain regions²¹. In the State of Maranhão knowledge of the genetic variations of *Plasmodium vivax* is incipient²², indicating the need for more research in this area for a clearer definition of this association. The National Plan for Malaria Control establishes early diagnosis and treatment as one of its main goals, toward reducing severity, mortality and disease transmission. It has been verified that although the State of Maranhão has shown a systematic reduction in the number of malaria cases in recent years², it still has difficulties in diagnosing the total number of cases within 48h of onset of symptoms, which could reduce the development of complications.

ACKNOWLEDGMENTS

We gratefully acknowledge Dr. Vanize Macedo *in memoriam* for her contribution in the initial part of this study and Dr. Elizabeth Carmem Duarte and Dr. Ana Nogaes (University of Brasília) for statistical analysis.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest.

FINANCIAL SUPPORT

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES).

REFERENCES

1. Ministério da Saúde. Secretaria de Vigilância em Saúde. Guia de Vigilância Epidemiológica. Série A. Normas e Manuais Técnicos. Caderno 10. 7ª ed. Brasília: Ministério da Saúde; 2009.

2. Silva AR, Fernandes JMC, Rodrigues TA, Santos HJ, Cavalheiro NNM, Guimaraes MC, et al. Controle da malária no Estado do Maranhão. Rev Soc Bras Med Trop 2009; 42:318-324.

3. Ministério da Saúde. Secretaria de Vigilância em Saúde. Sistema Nacional de Vigilância em Saúde: relatório de situação: Maranhão. Série C. Projetos, Programas e Relatórios. 2ª. ed Brasília: Ministério da Saúde; 2006.

4. Sistema de Informação de Vigilância Epidemiológica (SIVEP). Malária. Notificação de casos [Internet]. Brasília: Ministério da Saúde; 2011. [Cited 2012 August 3]. Available from: www.ses.gov.br/malaria/.

5. Islam N, Qamruddin K. Unusual complications in benign tertian malaria. Trop Geograph Med 1995; 47:141-143.

6. Alecrim MGC. Estudo clínico, resistência e polimorfismo parasitário na malária pelo *Plasmodium vivax*, em Manaus - AM. [Doctors Thesis]. [Brasília]: Universidade de Brasília; 2000. p.177.

7. Mohapatra MK, Padhiary KN, Mishar DP. Sathy. Atypical manifestations of *Plasmodium vivax* malaria. Indian J Malariol 2002; 39:18-25.

8. Echeweri M, Tobin A, Alvarez G, Carmona J, Blair S. Clinical and laboratory findings of *Plasmodium vivax* malaria in Colômbia, 2001. Rev Inst Med Trop Sao Paulo 2003; 45:29-34.

9. Lacerda MVG, Alexandre MAA, Santos PD, Alecrim WD, Alecrim MGC. Idiopathic thrombocytopenic purpura due to vivax malaria in the Brazilian Amazon. Acta Trop 2004; 90:187-190.

10. Rodrigues-Morales AJ, Sánchez E, Vargas M, Piccolo C, Colina R, Arria M. Anemia and thrombocytopenia in children with *Plasmodium vivax* malaria. J Trop Pediatrics 2005; 24:32.

11. Instituto Brasileiro de Geografia e Estatística (IBGE). Censo 2010 [Internet]. Dados Maranhão. [Cited 2012 August 3] Available from: http://www.censo2010.ibge.gov.br/dados_divulgados/index.php?uf=21/.

12. Ministério da Saúde. Secretaria de Vigilância em Saúde. Manual de diagnóstico laboratorial da malária. Série A. Normas e Manuais Técnicos. Brasília: Ministério da Saúde; 2005.

13. Ribeiro MCT, Gonçalves EGR, Tauil PL, Silva AR. Aspectos epidemiológicos de um foco de malária no município de São Luis, MA. Rev Soc Bras Med Trop 2005; 38:272-274.

14. Silva AR, Tauil PL, Bastos Júnior JL, Matos WB, Costa EAP, Gonçalves EGR. Aspectos da transmissão focal de malária na Ilha de São Luis, Maranhão. Rev Soc Bras Med Trop 2006; 39:250-254.

15. Oh MD, Shin H, Shin D, Kim U, Lee S, Kim N, et al. Clinical aspects of *vivax* malaria. Am J Trop Med Hyg 2001; 65:143-146.

16. Marsh KM, Crawle J, Peshu N. The pathogenesis of severe malaria in african children. Ann Trop Med Parasitol 1996; 90:395-402.

17. Singh H, Parakh A, Basu S, Rath B. *Plasmodium vivax* malaria: is it actually benign? J Infect Public Health 2011; 4:91-95.

18. Anstey NM, Jacups SP, Cain T, Pearson T, Ziezing PJ, Fisher DA, et al. Pulmonary manifestations of uncomplicated falciparum and vivax malaria: cough, small airways obstruction, impaired gas transfer and increased pulmonary phagocytic activity. J Infect Dis 2002; 185:1326-1334.

19. Maheshwari A, Singh AK, Sinha DK, Tripathi K, Prakash J. Spectrum of renal disease in malaria. J Indian Med Assoc 2004; 102:143-148.

20. Alexandre MA, Ferreira CO, Siqueira AM, Magalhães BL, Mourão MPG, Lacerda MV, et al. Severe *Plasmodium vivax* Malaria, Brazilian Amazon. Emerg Infect Dis 2010; 16:1611-1614.

21. Machado RLD, Povoas MM. Distribution of *Plasmodium vivax* variants (VK 210, VK 247 and *P. vivax* - like) in the endemic areas of the Amazon Region of Brazil and their correlation with chloroquine treatment. Trans R Soc Med Hyg 2000; 94:377-381.

22. Gonçalves EGR, Machado RLD, Santos AR, Raposo CCBS, Matos WB, Silva AR. Caracterização de genótipos de *Plasmodium vivax* na Ilha de São Luis, Maranhão. Rev Soc Bras Med Trop 2009; 42:315-317.